BreatheSuite

BreatheSuite A Medical Device

in your pocket

Eric Larson,

PhD Candidate,

Electrical Engineering.

Commercialized past

patent to Belkin.

Co-lead on

BreatheSuite’s patents.

Matt Jasper,

MBA Candidate

Founded 2 IP

licensing businesses.

Handles customer

development.

Mayank Goel,

PhD Candidate,

Computer Science.

Founded home

automation business.

Co-lead on

BreatheSuite’s

patents.

BreatheSuite Team

Shwetak Patel UW Professor in CSE &

EE,

MacArthur Genius Grant

Recipient

Jim Stout, MD UW Medicine, Spirometry

360 Creator, Primary Care

Physician

Margaret

Rosenfeld, MD Seattle Children’s

Hospital, Clinical

Pulmonologist

Rachael Tanner &

Kathie Jordan, Coulter Foundation

David Hammond, Regulatory Consultant

Greg Free, GSEC Mentor

Board of Advisors

Asthma

COPD

Cystic Fibrosis

Chronic Respiratory Disease

World Health Organization

World Asthma Foundation

1 out of every 7 people

have a respiratory

disease

Diagnosis: Spirometer

measures volume and

flow of air from the lungs

90% of hospitals in developing

nations do not have spirometers

Solution: BreatheSuite

From Any Phone

Everyone has access

BreatheSuite’s Impact

Reduce hospitalizations

Fewer deaths

Head To Head Evaluation


Test results identical

International Conference on Ubiquitous Computing, 2012


Test results identical

Doctor diagnosis identical

International Conference on Ubiquitous Computing, 2012

Current Status

Traction: In The News

Traction: Key Customers


Global Health Non-

Profits

Global Health Non-Profits

Handles: Developing World Healthcare

Needs: mHealth solutions

Global Health Market

1 Billion People

6 Billion Phones



Global Health Non-

Profits


Pharmaceuticals Global Health Non-

Profits

Pharmaceuticals: Clinical Trials

Market: 6000+ respiratory trials

Cost: $1 B per drug

Time: 15 years per drug

Go To Market

Pharmaceuticals

Developing World

Secondary Markets

Business Model

Pharmaceuticals Global Health Non-

Profits

Setup fee

Per Trial, Per Patient fee

Shared Distribution Channels

Paid Use Model via Buyers

Competition Full Diagnosis

Limited Diagnosis

Software Hardware

Spirometers

Peak Flow Meters FEV1 Meters

BreatheSuite

Financial Summary

$-

$10

$20

$30

$40

$50

$60

20132014

2015

Mill

ions

2013 2014 2015

Revenue $7 $21 $41

Net Income $3 $10 $18

Break Even

in Year 1

M M M

M M M

Social Return On Investment


Fewer deaths from COPD and asthma a 10% reduction = 325,000 lives

return of 65M – 1.3B dollars per year


Burden of Obstructive Lung Disease



Fewer hospitalizations a 10% reduction > 1M hospital stays

return of 600M – 4B dollars per year


Burden of Obstructive Lung Disease



Every dollar spent =

conservative: 2.6 dollars of impact

more realistic: 8.6 dollars of impact

Offer

Grant Funding:

$800,000

with $100,000

committed

Equity Funding:

$3M-$5M

Grant funding:

commercialization &

regulatory approval

Equity Funding:

Technology scaling &

sales

Thank you

Thanks to:

Deb Wolf & the GSEC staff,

Greg Free

GSEC judges and volunteers

BreatheSuite’s board of advisors

The University of Washington


in your pocket

www.breathesuite.com

[email protected]

@breathesuite


in your pocket

Appendix: How It Works

Audio

Vocal Tract

Model

Flow rate

Appendix: Side By Side Comparison

Raw Audio: 5.2%

Call In Service: 6.4%

ATS Range: 5-7%

Appendix: Leading Causes of Death


Appendix: Disability Adjusted Life Years

Global Burden of Disease, 2007

Appendix: Financials: Pharma Pharma Revenue Projections

Pharma Cost Projections

Appendix: Financials: Dev World

Dev World Cost Assumptions

Dev World Revenues have not been factored into our overall initial BreatheSuite revenue projections, as the Pharma Revenue is more than enough to cover both pharma and dev world costs. However, we are building out a paid use model with developing world global health partners that includes revenue that will both cover costs, provide healthy margins, and be affordable to those who need our technology the most.

Appendix: Income Statement & FCF

Appendix: Social Impact Summary

Inputs Outputs Outcomes Impacts

$8 M-$39 M

$220M-$2.4 B

$2 B-119 B

$9 B-$365 B

Drugs brought to market quicker

Increased rates of smoking cessation

Less hospitalization, self management of

disease, better health

More trials have integrated

spirometry results

Spirometry provides teaching moment for

smokers

Increased number of people performing

spirometry


spirometry

Cost of application, cost of training in

new trials

Doctors, Education & Ad Campaigns,

Application Services

Time, Access to phone, Remote Care

Workers, Doctors


Workers, Doctors

Pharmaceuticals Developing

Respiratory Drugs


Undiagnosed COPD patients

Undiagnosed Asthma Patients

Stakeholders



Total Impact $40 B – $524 B

$8 M-$39 M

$220M-$2.4 B

$20 B-119 B

$20 B-$365 B

Appendix: Social Impact Summary

Inputs Outputs Outcomes Impacts

$8 M-$39 M

$220M-$2.4 B

$20 B-119 B

$20 B-$365 B

Drugs brought to market quicker

Increased rates of smoking cessation



More trials have integrated

spirometry results

Spirometry provides teaching moment for

smokers


spirometry


spirometry

Cost of application, cost of training in

new trials

Doctors, Education & Ad Campaigns,

Application Services


Workers, Doctors


Workers, Doctors

Pharmaceuticals Developing

Respiratory Drugs


Undiagnosed COPD patients

Undiagnosed Asthma Patients

Stakeholders



Totals $40 B – $524 B

$4.1B/yr $10.6B-$35B/yr

BreatheSuite

Health & Medicine

Transcript of BreatheSuite